

surgery was not associated with increased hazard of overall death (HR 0.8 95% CI 0.4–1.5) or cancer-specific death (HR 1.0 95%CI 0.5–2.4). Small number of deaths limited precision of results.

**Conclusion** Fertility-sparing surgery was not associated with increased risk of death compared to standard surgery among reproductive-age epithelial ovarian cancer survivors with stage IA or IC disease.

2022-RA-848-ESGO

#### OBSTETRIC AND NEONATAL OUTCOMES AFTER BREAST CANCER: A POPULATION-BASED STUDY

<sup>1</sup>Kirsten Jorgensen, <sup>1</sup>Roni Nitecki, <sup>2</sup>Hazel Nichols, <sup>1</sup>Shuangshuang Fu, <sup>1</sup>Chi-Fang Wu, <sup>3</sup>Alexander Melamed, <sup>4</sup>Paula Brady, <sup>1</sup>Mariana Chavez-Mac Gregor, <sup>5</sup>Mark Clapp, <sup>1</sup>Sharon Giordano, <sup>1</sup>Jose Alejandro Rauh-Hain. <sup>1</sup>*Gynecological Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX*; <sup>2</sup>*Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC*; <sup>3</sup>*Obstetrics and Gynecology, Division Gynecologic Oncology, New York-Presbyterian/Columbia University Medical Center, New York, NY*; <sup>4</sup>*Obstetrics and Gynecology, Division Reproductive Endocrinology, New York-Presbyterian/Columbia University Medical Center, New York, NY*; <sup>5</sup>*Obstetrics and Gynecology, Maternal-Fetal Medicine Program, Massachusetts General Hospital, Boston, MA*

10.1136/ijgc-2022-ESGO.376

**Introduction/Background** To evaluate obstetric and neonatal outcomes of the first live birth conceived following breast cancer diagnosis.

**Methodology** We performed a population-based study to compare live births between women with a history of breast cancer and matched controls with no cancer history. Cases and controls were identified using linked data from the California Cancer Registry and California Office of Statewide Health Planning and Development datasets. Cases were diagnosed with stage I-III breast cancer at ages 18–45 years between January 1, 2000, and December 31, 2012, and conceived  $\geq 12$  months after breast cancer diagnosis. Controls were covariate-matched women without a history of breast cancer who delivered during 2000–2012. The primary outcome was preterm birth  $< 37$  weeks. Secondary outcomes were preterm birth  $< 32$  weeks, small for gestational age, cesarean delivery, severe maternal morbidity, and neonatal morbidity. Subgroup analyses were used to assess time from initial treatment to conception and receipt of additional adjuvant therapy prior to pregnancy on outcomes of interest.

**Results** Of 30,021 women age 18–45 diagnosed with stage I-III breast cancer during 2000–2012, 553 met the study inclusion criteria. Those with a history of breast cancer and matched controls had similar odds of preterm birth  $< 37$  weeks (odds ratio [OR], 1.29; 95% CI, 0.95–1.74), preterm birth  $< 32$  weeks (OR, 0.77; 95% CI, 0.34–1.79), delivering a small for gestational age neonate ( $< 5$ th percentile: OR, 0.60; 95% CI, 0.35–1.03;  $< 10$ th percentile: OR, 0.94; 95% CI, 0.68–1.30), and experiencing severe maternal morbidity (OR, 1.61; 95% CI, 0.74–3.50). Patients with a history of breast cancer had higher odds of undergoing a cesarean delivery (OR, 1.25; 95% CI, 1.03–1.53), however their offspring did not have increased odds of neonatal morbidity compared to controls (OR, 1.15; 95% CI, 0.81–1.62).

**Conclusion** Breast cancer history was not strongly associated with obstetric and neonatal complications.

2022-RA-870-ESGO

#### FERTILITY OUTCOME OF PATIENTS WITH STAGE I IMMATURE TERATOMA – DO SURGICAL APPROACH AND POST-SURGICAL TREATMENT MATTER?

<sup>1</sup>Giuseppe Marino, <sup>2</sup>Tommaso Grassi, <sup>1</sup>Filippo Testa, <sup>1</sup>Serena Negri, <sup>3</sup>Elena de Ponti, <sup>2</sup>Daniela Giuliani, <sup>1</sup>Martina Delle Marchette, <sup>2</sup>Federica Paola Sina, <sup>1</sup>Diletta Fumagalli, <sup>1</sup>Debora Vicini, <sup>1</sup>Mariaclara Boccadutri, <sup>2</sup>Maria Cristina Bonazzi, <sup>2</sup>Fabio Landoni, <sup>2</sup>Robert Fruscio. <sup>1</sup>*Obstetrics and Gynaecology, University of Milano-Bicocca, Monza, Italy*; <sup>2</sup>*San Gerardo Hospital, Obstetrics and Gynaecology Department, Monza, Italy*; <sup>3</sup>*San Gerardo Hospital, Medical Physics Department, Monza, Italy*

10.1136/ijgc-2022-ESGO.377

**Introduction/Background** Immature teratomas (ITs) are a rare disease representing about one-third of all malignant ovarian germ cell tumors. They are frequently diagnosed in young women, with a peak at 15–30 years old, when the childbearing desire is not completed. Thus, fertility-sparing surgery (FSS) is the treatment of choice, followed by adjuvant chemotherapy (CT) in patients with high-risk features. We investigated the effect of CT on fertility outcome in stage I any grades ITs, also focusing on the effect of the type of ovarian surgery (unilateral salpingo-oophorectomy (USO) vs cystectomy (Cy)) on the same outcome.

**Methodology** Clinicopathological data were retrospectively collected and analyzed from a cohort of 74 patients with stage I ITs treated at San Gerardo Hospital (Monza, Italy). Forty-seven patients who manifested pregnancy desire and underwent a FSS were enrolled.

**Results** Among the 47 patients included 37 patients (78,7%) reached pregnancy. The pregnancy rate was not significantly different neither between adjuvant CT and surveillance group (62.5% and 82.0%, respectively [ $p = 0.21$ ]), nor between USO vs Cy group (79,4% and 76,9%, respectively [ $p = 0.57$ ]). The only statistical significant difference was found for staging (a decrease in pregnancy rate from 86.5% for stage IA to 50.0% for stage IC [ $p = 0.02$ ]), but no factors reached a significant impact on the fertility outcome in a multivariate analysis. Interestingly, 62,5% of patients who relapsed reached a pregnancy.

**Conclusion** These data confirm that a fertility sparing approach is feasible in this young population, and the fertility outcome does not depend on surgical approach or post-surgical treatment. More prospective data are needed, and the role of stage of disease must be fully investigated.

2022-RA-962-ESGO

#### CANCER IN PREGNANCY: MESSAGE IN A BOTTLE FROM TERTIARY CENTER OF MILAN

<sup>1</sup>Cristina Maria Michela Matozzo, <sup>1</sup>Anna Viscardi, <sup>1</sup>Eugenia Di Loreto, <sup>1</sup>Elena Grossi, <sup>2</sup>Veronica Accurti, <sup>1</sup>Beatrice De Luca Carignani, <sup>1</sup>Carlotta Castellani, <sup>1</sup>Giovanna Scarfone. <sup>1</sup>*Gynaecology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy*; <sup>2</sup>*Maternal-fetal medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy*

10.1136/ijgc-2022-ESGO.378

**Introduction/Background** Cancer complicates approximately 0.1% of all pregnancies. The management represent a challenge because the need of balancing the risks for mother and baby. This study reports our experience in oncological and obstetrical care in patients with cancer in pregnancy (CIP).